Sloan to Lead New University Hospitals Center of Excellence for Translational Neuro-Oncology

Following evaluation of faculty-led proposals, the leadership of the University Hospitals (UH) Research Division has announced the establishment of their first two Centers of Excellence (COEs): the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) and the Center for Excellence for Translational Neuro-Oncology (CETNO).

Andrew E. Sloan, M.D.

CETNO will be led by Andrew E. Sloan, MD, the Peter D. Cristal Chair of Neurosurgical Oncology, Director, Brain Tumor and Neuro-Oncology Center and senior neurosurgeon at UH. Dr. Sloan is also a member of the Developmental Therapeutics and Cancer Imaging Programs in the Case CCC. 

The center will focus on critical challenges in neuro-oncology that limit clinicians' abilities to understand and follow responses in brain tumor treatment. Among these challenges are the paucity and lack of specificity of biomarkers along with intra-tumoral heterogeneity. Bringing together multiple departments and centers at UH, CETNO will create a unique platform to advance the understanding and treatment of brain tumors. An RFI is slated to be released next month.